---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001045"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:21:29.545904+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "low"
source: SEC EDGAR
---

# MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025

## Summary
- Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.
- Trial evaluates THIO sequenced with cemiplimab in advanced NSCLC patients after 2+ prior therapies.
- Poster copy filed as Exhibit 99.1 and posted on company website; no specific numeric results in 8-K text.
- Data disclosure under Regulation FD; forward-looking statements caution against undue reliance.

## SEC filing metadata
- accession: 0001641172-25-001045
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/0001641172-25-001045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225001045/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001045
- JSON: https://secwatch.observer/filing/0001641172-25-001045.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.